Xiaowen Mao | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Assist. Prof. Dr. Xiaowen Mao | Medicine and Health Sciences | Best Researcher Award

University of Macau | Macau

Dr. Xiaowen Mao, M.D., Ph.D., is an Assistant Professor at the State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, where she leads translational research on cancer biology, immunotherapy, and tumor microenvironment modulation. She earned her Ph.D. in Biomedical Sciences from the University of Hong Kong and her B.Sc. in Clinical Medicine from Shanghai Jiao Tong University, China. Her research focuses on extracellular vesicles, immune homeostasis, metabolic reprogramming in tumors, and hepatocellular carcinoma metastasis, integrating molecular, cellular, and translational approaches. Dr. Xiaowen Mao has led several high-impact projects as principal investigator, funded by the Health and Medical Research Fund, National Natural Science Foundation Young Scientist Fund, and FDCT Innovation and Technology Promotion. Her significant contributions include the development of broadly potent neutralizing antibodies targeting Nidogen 1 to inhibit tumor growth, elucidation of extracellular vesicle-mediated metabolic reprogramming in tumors, and advances in dendritic cell vaccine strategies. She holds a U.S. patent on Nidogen 1 as a diagnostic and therapeutic target for hepatocellular carcinoma, serves as Guest Editor for Frontiers in Endocrinology, and is an ad-hoc reviewer for multiple high-impact journals. According to Scopus, she has 31 publications, 1,114 citations by 1,010 documents, and an h-index of 20. Dr. Xiaowen Mao’s work bridges fundamental research and clinical translation, delivering innovative therapies and advancing precision medicine in oncology, while demonstrating a profound impact on cancer biology, immunotherapy, and translational research.

Profile: Scopus

Featured Publications

  • Xue, T. M., Yeung, C. L. S., Mao, X. W., Tey, S. K., Lo, K. W., Tang, H. N., Yun, J. P., & Yam, J. W. P. (2025). Development of a broadly potent neutralizing antibody targeting Nidogen 1 effectively inhibits cancer growth and metastasis in preclinical tumor models. Journal of Translational Internal Medicine. https://doi.org/10.1515/jtim-2025-0008

  • Xia, L., Li, C. G., Zhao, J., Sun, Q. C., & Mao, X. W.* (2025). Rebalancing immune homeostasis in combating disease: The impact of medicine food homology plants and gut microbiome. Phytomedicine, 136, 156150. https://doi.org/10.1016/j.phymed.2025.156150

  • Chen, Z., Yam, J. W. P., & Mao, X. W.* (2024). The multifaceted roles of small extracellular vesicles in metabolic reprogramming in the tumor microenvironments. Proteomics, e2300021. https://doi.org/10.1002/pmic.202300021

  • Lee, K. W., Yam, J. W. P., & Mao, X. W.* (2023). Dendritic cell vaccines: A shift from conventional approach to new generations. Cells, 12(2147). https://doi.org/10.3390/cells12172147

  • Li, S., Delvecchio, M., Ramkumar, K., Mao, X. W., Sun, X. D., & Guo, S. Z. (2023). Editorial: Clinical and genetic determinants of diabetes and complications. Frontiers in Endocrinology.

Sahar Issa | Health Professions | Best Researcher Award

Published on by Forensic Scientist

Prof. Dr. Sahar Issa | Health Professions | Best Researcher Award

Faculty of medicine, Alexandria University | Egypt

Dr. Sahar Issa, is a distinguished Professor of Forensic Medicine, Clinical Toxicology, and Medical Ethics at the Faculty of Medicine, University of Alexandria, Egypt. She earned her Ph.D. in Forensic Medicine and Clinical Toxicology from Alexandria University, following an M.Sc. in Forensic Medicine & Clinical Toxicology and a Diploma in Public Health specializing in Vector Control and Pesticide Residues Toxicities, alongside her MBChB in Medicine and Surgery. Over her extensive academic career, Dr. Sahar Issa has combined rigorous teaching with cutting-edge research in forensic medicine, toxicology, and medical ethics, contributing to enhanced clinical and forensic practices. Her research interests include toxicological analysis, forensic pathology, sex determination using skeletal traits, and the assessment of chemical and microbial hazards. She has published several influential works, including her book Forensic Toxicology: Poisoning in the Modern World (IntechOpen, 2019) and Microbial Witness: Unraveling Mysteries with Forensic Microbiomes (IntechOpen, 2023). Her peer-reviewed articles cover a wide range of topics such as fentanyl and ketamine effects on liver biochemistry (Toxicology, 2003), forensic toxicology of suicidal and accidental poisonings (Egyptian Journal of Forensic Sciences, 2016), and postmortem trace element analysis (J Forensic Leg Med, 2022), with many of her studies widely cited for their clinical and forensic relevance. Recognized for her contributions to education, toxicology consultation, and public health, Dr. Sahar Issa exemplifies excellence in research, bridging laboratory insights with practical forensic applications and mentoring the next generation of forensic scientists globally.

Profile: Google Scholar | ORCID | LinkedIn

Featured Publications

Hafez, E. M., Issa, S. Y., Ai-Mazroua, M. K., Ibrahim, K. T., & Rahman, S. M. A. (2016). The neonicotinoid insecticide imidacloprid: A male reproductive system toxicity inducer-human and experimental study.

Hafez, M. E., Issa, Y. S., & Abdel Rahman, M. S. (2015). Parenchymatous toxicity of tramadol: Histopathological and biochemical study. Journal of Alcohol and Drug Dependence, 3(5), 225.

Issa, S. Y., Khanfour, A. A., & Kharoshah, M. (2016). A model for stature estimation and sex prediction using percutaneous ulnar and radial lengths in autopsied adult Egyptians. Egyptian Journal of Forensic Sciences, 6(2), 84–89.

Ibrahim, S. Y. (2016). Determination of heavy metals and other toxic ingredients in henna (Lawsonia inermis). Journal of Environmental & Analytical Toxicology, 6(3), 9.

Cebolla, S. G., [et al.]. (2018). Fully automated forensic routine dried blood spot screening for workplace testing. Journal of Analytical Toxicology, 43(2), 1–11.

Issa, S. Y., Hafez, E. M., El-Banna, A. S., Abdel Rahman, S. M., AlMazroua, M. K., … [et al.]. (2018). Baclofen systemic toxicity: Experimental histopathological and biochemical study. Human & Experimental Toxicology, 37(4), 431–441.

Zagloul, N. M., Farghaly, R. M., ELKhatib, H., Issa, S. Y., & El-Zoghby, S. M. (2022). Technology facilitated sexual violence: A comparative study between working and non-working females in Egypt before and during the COVID-19 pandemic. Egyptian Journal of Forensic Sciences, 12(1), 21.

Alalawi, S., Issa, S. T., Takshe, A. A., & ElBarazi, I. (2022). A review of the environmental implications of the COVID-19 pandemic in the United Arab Emirates. Environmental Challenges, 8, 100561.

Eddine, N. N., Noisel, N., Dieme, D., Asmar, M. K., Issa, S. T., & Bouchard, M. (2022). Multi-matrix biomonitoring approach to assess exposure to metals and trace elements in the Lebanese population and associations with drinking water consumption. Environmental Research, 214, 113982.

Yang Xu | Medicine | Best Researcher Award

Published on by Forensic Scientist

Dr. Yang Xu | Medicine | Best Researcher Award

Associate chief physician | Department of Respiratory and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital | China

Yang Xu is an Associate Chief Physician, Associate Professor, and Graduate Supervisor at the Department of Respiratory and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital. Specializing in the early diagnosis and personalized treatment of lung tumors, Dr. Xu has made significant contributions to respiratory medicine and oncology. As a leading expert in the field, he has played a pivotal role in advancing immune purification and cell therapy, earning widespread recognition for his scientific achievements.

Profile

ORCID

Strengths for the Awards

✅ Expertise in Lung Tumor Diagnosis & Treatment: Yang Xu specializes in the early diagnosis and personalized treatment of lung tumors, which is a crucial area in respiratory and critical care medicine.

✅ Strong Research Contributions: With 6 funded research projects, including National Natural Science Foundation of China and key national R&D plans, his research impact is significant.

✅ Recognition & Patents: Winning 1 medical science and technology progress award and holding 4 national invention patents showcase his innovation and contribution to medical advancements.

✅ Publication Record: Publishing 40 research papers, including 20 SCI-indexed papers, and editing 5 monographs as a deputy principal author indicates a high level of scholarly contribution.

✅ Leadership & Influence: Holding leadership positions in prestigious medical associations such as the Chinese Medical Association and Beijing Medical Association reflects his influence in the field.

🎓 Education

Dr. Xu received his medical education and advanced training in respiratory and critical care medicine, equipping him with the expertise to diagnose and treat complex lung diseases. His academic journey has been marked by rigorous research and continuous professional development in cutting-edge medical technologies.

👨‍⚕️ Experience

With extensive experience in respiratory and critical care medicine, Dr. Xu has led multiple national research projects, including those funded by the National Natural Science Foundation of China and the national key R&D plan. As an esteemed educator and mentor, he has guided numerous students in the field, shaping the next generation of medical professionals. His leadership extends to prestigious roles such as Deputy Leader of the Immune Purification and Cell Therapy Group under the Chinese Medical Association and Deputy Chairman of the Lung Cancer Group in the Respiratory Branch of the Beijing Medical Association.

🔬 Research Interests On Medicine

Dr. Xu’s research focuses on:

  • Lung Tumor Diagnosis & Treatment – Advancing early detection and precision therapy.
  • Immune Checkpoint Inhibitor Pneumonia – Contributing to China’s first expert consensus.
  • Strategic Advanced Electronic Materials – Investigating innovative medical applications.
  • Immune Purification & Cell Therapy – Exploring novel therapeutic strategies in respiratory medicine.

🏆 Awards

Dr. Xu has received numerous accolades for his contributions to medical science, including:

  • Medical Science & Technology Progress Award 🏅
  • 4 National Invention Patents 🏅🏅🏅🏅
  • Excellent Doctor & Excellent Teacher Titles 🏆 (Multiple times)
  • Selected as China’s High-Level Scientific and Technological Innovation Talent 🌟

📚 Publications

  1. Clinic Examination and Gene Diagnosis for a Birt–Hogg–Dubé Syndrome Family With a Novel flcn Frameshift Mutation Causing Nonsense‐Mediated mRNA Degradation
    • Authors: Yang Xu, Jie Gao, Yang An, Chenxi Zou, Guoqing Ding, Guohua Yang
    • Year: 2025
  2. [Clinical diagnosis and treatment of lung cancer combined with interstitial lung disease]
    • Author: Xu Y
    • Year: 2024
  3. Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer
    • Authors: Yabin Chen, Fang Z, Tang Y, Jin Y, Guo C, Hu L, Xu Y, Ma X, Gao J, Xie M et al.
    • Year: 2021
  4. Clinical characteristics of patients with chronic eosinophilic pneumonia in a Chinese tertiary-care hospital: A 6-year retrospective study
    • Authors: Xu Y, Wang Z, Li W, Zhu Q, Liang Z
    • Year: 2021
  5. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis
    • Authors: Huang A, Xu Y, Zang X, Wu C, Gao J, Sun X, Xie M, Ma X, Deng H, Song J et al.
    • Year: 2021
  6. Perfluorocarbon Protects against Lipopolysaccharide-Induced Apoptosis of Endothelial Cells in Pulmonary Microvessels
    • Authors: Xu Y, Wu T, Wang P, Liang ZX, Shi SS, Xu SF, Liu XJ, Tian Q
    • Year: 2021
  7. Lung cancer treatment in the era of immunotherapy
    • Authors: Xu Y, Liang-an Chen
    • Year: 2020
  8. The efficacy and safety of low-frequency rotating static magnetic field therapy combined with chemotherapy on advanced lung cancer patients: a randomized, double-blinded, controlled clinical trial
    • Authors: Minghui Zhu, Yang Z, Hang Yu, Zhu Q, Xu Y, Li Y, Li C, Zhao W, Zhixin Liang, Liang-an Chen
    • Year: 2020
  9. Identification of differentially expressed genes in hip cartilage with femoral head necrosis, based on genome‑wide expression profiles
    • Authors: Li WC, Bai L, Xu Y, Xu RJ, Hou WB
    • Year: 2019
  10. Cystic and solitary nodular pulmonary metastases in a patient with low-grade endometrial stromal sarcoma: A case report and literature review
  • Authors: Xu Y, Zhixin Liang, Guo JT, Su X, Lu YL, Guan XZ
  • Year: 2019

🔚 Conclusion

Yang Xu is a distinguished leader in respiratory and critical care medicine, driving innovation in lung cancer treatment and immune-related diseases. His contributions to research, education, and clinical practice continue to shape the future of respiratory medicine, making a lasting impact on both national and global healthcare communities.